Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q4 2022 Earnings Call Transcript

Page 5 of 5

Jay Olson: Okay, great. Thank you. That’s super helpful. Appreciate that, Sergio. And thank you both.

Sergio Traversa: Thank you.

Operator: We’ve reached the end of the question-and-answer session. I would now like to turn the call back to Sergio Traversa for closing comments.

Sergio Traversa: Thank you very much. And in closing, I remain grateful to the Relmada team for their continued hard work and dedication to executing on our mission. I would like also to extend my sincere thanks to the participants and clinical partners involved in the REL-1017 trials for the effort in advance of this important product candidate through the clinic. With that said, thank you very much to everyone, and I wish to everyone a good end of the day. Thank you.

Operator: This concludes today’s conference. You may disconnect your lines at this time, and we thank you for your participation.

Follow Relmada Therapeutics Inc. (NASDAQ:RLMD)

Page 5 of 5